BioNexus Gene Lab (BGLC) Change in Account Payables (2018 - 2026)

BioNexus Gene Lab has reported Change in Account Payables for 9 years, with the latest figure at $187891.0 in Q1 2026.

• Quarterly Change in Account Payables rose 159.17% year-over-year to $187891.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$878075.0 (down 421.4% YoY) and the FY2025 annual result came in at -$1.4 million, down 777.05% from the prior year.
• Change in Account Payables improved to $187891.0 in Q1 2026 per BGLC's latest filing, from -$156034.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $649741.0 in Q4 2022 and troughed at -$1.1 million in Q3 2025.
• A 5-year average of -$87779.0 and a median of -$133742.0 in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables surged 2871.49% in 2024, then slumped 674.94% in 2025.
• Over 5 years, Change in Account Payables stood at $649741.0 in 2022, then plunged by 102.57% to -$16676.0 in 2023, then soared by 2871.49% to $462174.0 in 2024, then slumped by 133.76% to -$156034.0 in 2025, then soared by 220.42% to $187891.0 in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $187891.0, -$156034.0, and -$1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.